GelTex Incorporated Company Profile
We are dedicated to having a positive effect on the lives of people living with illness and disease. We have demonstrated this by bringing important new therapies from discovery to market. GelTex’s first product, Renagel® brand sevelamer hydrochloride, was granted marketing approval by the U.S. Food and Drug Administration (FDA) in October 1998 for the reduction of serum phosphorus in hemodialysis patients.
In addition, WelCholTM brand colesevelam hydrochloride was granted marketing approval by the FDA in May 2000, for the treatment of hypercholesterolemia, a condition characterized by undesirably high blood cholesterol levels.
153 Second Avenue
United States of America
Phone: 781 290 5888
Fax: 781 290 5890
Drugs and Medications
GelTex Pharmaceuticals, Inc. is developing non-absorbed, polymer-based pharmaceuticals that selectively bind to andeliminate target substances from the intestinal tract. In October 1998, the Company r...
We are dedicated to having a positive effect on the lives of people living with illness and disease. We have demonstrated this by bringing important new therapies from discovery to market. GelTex’s ...
More Information about "GelTex Incorporated" on BioPortfolio
We have published hundreds of GelTex Incorporated news stories on BioPortfolio along with dozens of GelTex Incorporated Clinical Trials and PubMed Articles about GelTex Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GelTex Incorporated Companies in our database. You can also find out about relevant GelTex Incorporated Drugs and Medications on this site too.